FORM 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

Quarterly Report Under Section 13 or 15(d)
of the Securities and Exchange Act of 1934

For the quarter ended: July 4, 1998   Commission File Number: 1-10730

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts	04-2882273
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

400 Wood Road, Braintree, MA 02184
(Address of principal executive offices)

Registrant's telephone number, including area code: (781) 848-7100

Indicate by check mark whether the registrant (1.) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) (2.) has been subject to the filing requirements for at least the past 90 days.

Yes X   No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

26,584,679 shares of Common Stock, $.01 par value, as of
July 4, 1998

HAEMONETICS CORPORATION
INDEX

		PAGE
PART I.	Financial Information	
	Consolidated Balance Sheets - July 4, 1998 and March 28, 1998	2
	Consolidated Statements of Operations - Three Months Ended July 4, 1998 and June 28, 1997	3
	Consolidated Statements of Stockholders' Equity - Three Months Ended July 4, 1998	4
	Consolidated Statements of Cash Flows - Three Months Ended July 4, 1998 and June 28, 1997	5
	Notes to Consolidated Financial Statements	6-9
	Management's Discussion and Analysis of Financial Condition and Results of Operations	10-12
PART II.	Other Information	13
	Signatures	14

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited - in thousands, except share data)

	July 4,	March 28,

ASSETS	1998	1998
Current assets:		
Cash and short term investments	$ 24,255	$ 21,766
Accounts receivable, less allowance of $840 at July 4, 1998 and $818 at March 28, 1998	57,126	58,886
Inventories	64,474	61,664
Current investment in sales-type leases, net	11,849	11,887
Deferred tax asset	20,852	21,777
Other prepaid and current assets	9,532	15,170
Total current assets	188,088	191,150
Property, plant and equipment	170,180	170,261
Less accumulated depreciation	87,346	86,042
Net property, plant and equipment	82,834	84,219
Other assets:		
Investment in sales-type leases, net (long term)	34,252	38,596
Distribution rights, net	9,956	10,718
Other assets, net	10,074	5,204
Property, plant and equipment and other assets net of long-term liabilities of discontinued operations	6,164	6,806
Total other assets	60,446	61,324
Total assets	$331,368	$336,693
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Notes payable and current maturities of long-term debt	$ 12,466	$ 17,468
Accounts payable	15,109	21,689
Accrued payroll and related costs	6,365	7,726
Accrued income taxes	8,213	5,750
Accrued value added tax	0	0
Other accrued liabilities	17,159	15,132
Current liabilities and accrued losses net of current assets of discontinued operations	7,518	10,593
Total current liabilities	66,830	78,358
Deferred income taxes	13,755	9,944
Long-term debt, net of current maturities	51,462	53,586
Other long-term liabilities	150	150
Stockholders' equity:		
Common stock, $.01 par value; Authorized - 80,000,000 shares; Issued 29,341,648 shares at July 4, 1998; 29,341,648 shares at March 28, 1998	293	293
Additional paid-in capital	59,166	59,142
Retained earnings	195,657	190,757
Cumulative translation adjustments	(9,996)	(9,588)
Stockholders' equity before treasury stock	245,120	240,604
Less: treasury stock 2,756,969 shares at cost at July 4, 1998 and 2,756,969 shares at cost at March 28, 1998	45,949	45,949
Total stockholders' equity	199,171	194,655
Total liabilities and stockholders' equity	$331,368	$336,693
Supplemental disclosure of balance sheet information:		
Net debt	$ 39,673	$ 49,288

The accompanying notes are an integral part of these consolidated financial statements.

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited - in thousands, except share data)

	Three Months Ended	
	July 4, 1998	June 28, 1997
Net revenues	$71,996	$79,485
Cost of goods sold	36,026	42,397
Gross profit	35,970	37,088
Operating expenses:		
Research and development	3,803	4,928
Selling, general and administrative	24,864	20,712
Total operating expenses	28,667	25,640

Operating income	7,303	11,448
Interest expense	(979)	(557)
Interest income	1,083	950
Other income, net	220	32
Income from continuing operations before provision for income taxes	7,627	11,873
Provision for income taxes	2,670	4,156
Earnings from continuing operations	$ 4,957	$ 7,717
Discontinued operations:		
Loss from operations, net of income tax benefit of ($31) in 1998 and ($666) in 1997	(57)	(1,236)
Net Income	$ 4,900	$ 6,481
Basic income(loss) per common share		
Continuing operations	$ 0.186	$ 0.290
Discontinued operations	(0.002)	(0.046)
Net income (loss)	0.184	0.244
Income(loss) per common share assuming dilution		
Continuing operations	$ 0.186	$ 0.290
Discontinued operations	(0.002)	(0.047)
Net income (loss)	0.184	0.243
Weighted average shares outstanding		
Basic	26,585	26,569
Diluted	26,627	26,645

The accompanying notes are an integral part of these consolidated financial statements.

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(in thousands)

	Common Stock Shares	Common Stock $'s	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Accumulated Cumulative Translation Adjustment	Total Stockholders' Equity	Comprehensive Income
Balance, March 28, 1998	29,342	$293	$59,142	($45,949)	$190,757	($9,588)	$194,655	
Employee stock purchase plan	---	---	---	---	---	---	0	
Exercise of stock options and related tax benefit	---	---	24	---	---	---	24	
Purchase of treasury stock	---	---	---	---	---	---	0	
Net Income	---	---	---	---	4,900	---	4,900	4,900
Foreign currency translation adjustment	---	---	---	---	---	(408)	(408)	(408)
Balance, July 4, 1998	29,342	$293	$59,166	($45,949)	$195,657	($9,996)	$199,171	$4,492

The accompanying notes are an integral part of these consolidated financial statements

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited- in thousands)

	Three Months Ended July 4, 1998	Three Months Ended June 28, 1997
Cash Flows from Operating Activities:		
Net income (loss)	$ 4,900	$ 6,481
Less net loss from discontinued operations	(57)	(1,236)
Net income from continuing operations	4,957	7,717
Adjustments to reconcile net income to net cash provided by operating activities:		

Non cash items:		
Depreciation, amortization and other	6,793	6,604
Deferred tax benefit (provision)	(261)	2
Change in operating assets and liabilities:		
(Increase) decrease in accounts receivable - net	1,574	(5,045)
(Increase) in inventories	(2,881)	(3,680)
(Increase) in sales-type leases (current)	(876)	(1,081)
(Increase) decrease in prepaid income taxes	7,725	(41)
(Increase) in other assets	(1,464)	(5,068)
Decrease in accounts payable, accrued expenses and other current liabilities	(2,371)	(5,048)
Net cash provided by (used in) operating activities, continuing operations	13,196	(5,640)
Net cash (used in) operating activities, discontinued operations	(2,306)	(584)
Net cash provided by (used in) operating activities	10,890	(6,224)
Cash Flows from Investing Activities:		
Capital expenditures on property, plant and equipment, net of retirements and disposals	(3,834)	(8,415)
Net (increase) decrease in sales-type leases (long-term)	2,750	(8,995)
Net cash (used in) investing activities, continuing operations	(1,084)	(17,410)
Net cash (used in) investing activities, discontinued operations	(186)	(695)
Net cash (used in) investing activities	(1,270)	(18,105)
Cash Flows from Financing Activities:		
Payments on long-term real estate mortgage	(50)	(226)
Net increase (decrease) in short-term revolving credit agreements	(5,038)	2,733
Net increase (decrease) in long-term credit agreements	(2,083)	23,633
Exercise of stock options and related tax benefit	24	820
Purchase of treasury stock	0	(5,566)
Net cash provided by (used in) financing activities	(7,147)	21,394
Effect of exchange rates on cash and cash equivalents	16	94
Net increase (decrease) in cash and cash equivalents	2,489	(2,841)
Cash and cash equivalents at beginning of period	21,766	8,272
Cash and cash equivalents at end of period	$24,255	$ 5,431
Supplemental disclosures of cash flow information:		
Net (decrease) in cash and cash equivalents, discontinued operations	($2,492)	($1,279)
Net increase (decrease) in cash and cash equivalents, continuing operations	$ 4,981	($1,562)
Increase (decrease) in net debt	($9,660)	$ 28,981
Interest paid	$ 444	$ 519
Income taxes paid (refunded)	($7,416)	$ 6,210

HAEMONETICS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PRESENTATION

The results of operations for the interim periods shown in this report are not necessarily indicative of results for any future interim period or for the entire fiscal year. The Company believes that the quarterly information presented includes all adjustments (consisting only of normal, recurring adjustments) that the Company considers necessary for a fair presentation in accordance with generally accepted accounting principles. The accompanying consolidated financial statements and notes should be read in conjunction with the Company's audited annual financial statements.

2. FISCAL YEAR

The Company's fiscal year ends on the Saturday closest to the last day of March. As a result, current fiscal year 1999 includes 53 weeks as compared to the normal 52 weeks. The additional week was added to the first quarter ended July 4, 1998 which, as a result, included 14 weeks. Fiscal year 1998 included 52 weeks with the first quarter, ended June 28, 1998 including 13 weeks.

3. COMPREHENSIVE INCOME

In June 1998, the Company adopted Statement of Financial Accounting Standard (SFAS) NO. 130, "Reporting Comprehensive Income." SFAS 130 requires the presentation, by major components and as a single total, the change in the Company's net assets during a period from non-owner sources. Currently, the Company's non-owner changes in equity are the foreign currency translation adjustments, which totaled ($9.9) million and ($9.6) million at July 4, 1998 and March 28, 1998, respectively.

4. NEW PRONOUNCEMENTS

In June 1997, the Financial Accounting Standards board, (FASB) issued

SFAS No. 131, "Disclosures about Segments of an Enterprise and Related Information". SFAS 131 requires companies to present segment information using the management approach. The management approach is based upon the way that management organizes the segments within a Company for making operating decisions and assessing performance. SFAS 131 is effective for the Company's 1999 annual financial statements. Adoption of this standard will not impact the Company's consolidated financial position, results of operations or cash flows, and any effect will be limited to the form and content of its disclosures.

In June 1998, FASB issued SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities. The Statement establishes accounting and reporting standards requiring that every derivative instrument (including certain derivative instruments embedded in other contracts) be recorded in the balance sheet as either an asset or liability measured at its fair value. The Statement requires that changes in the derivatives fair value be recognized currently in earnings unless specific hedge accounting criteria are met. Special accounting for qualifying hedges allows a derivative's gains and losses to offset related results on the hedged item in the income statement, and requires that a company must formally document, designate, and asses the effectiveness of transactions that receive hedge accounting. Statement 133 is effective for fiscal years beginning after June 15, 1999. A company may also implement the Statement as of the beginning of any fiscal quarter after issuance (that is fiscal quarters beginning June 16, 1998 and thereafter). Statement 133 cannot be applied retroactively. The impacts of adopting Statement 133 on the Company's financial statements or the timing of adoption of Statement 133 have not been determined. However, it is expected that the derivative financial instruments acquired in connection with the Company's hedging program will continue to qualify for hedge accounting.

5. FOREIGN CURRENCY

The Company enters into forward exchange contracts to hedge certain firm sales commitments to customers which are denominated in foreign currencies. The purpose of the Company's foreign hedging activities is to reduce uncertainty associated with currency movement in future periods. Gains and losses realized on these contracts are recorded in operations, offsetting the related foreign currency transactions. The cash flows related to the gains and losses on these foreign currency hedges are classified in the statements of cash flows as part of cash flows from operating activities.

At July 4, 1998 the Company had forward exchange contracts, all having maturities of less than one year, to exchange foreign currencies (major European currencies and Japanese yen) for US dollars totaling $94.5 million. Of that balance, $30.9 million represented contracts for terms of 30 days or less. Gross unrealized gains from hedging firm sales commitments, based on current spot rates, were $5.2 million at July 4, 1998. Deferred gains and losses are recognized in earnings when the transactions being hedged are recognized. Management anticipates that the deferred amounts will be offset by the foreign exchange effect on sales of product in future periods.

6. INVENTORIES

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.

Inventories consist of the following:

	July 4, 1998	March 28, 1998
	(in thousands)	
Raw materials	$15,331	$11,532
Work-in-process	5,817	5,878
Finished goods	43,326	44,254
	$64,474	$61,664

7. NET INCOME (LOSS) PER SHARE

In February 1997, the Financial Accounting Standards board issued SFAS NO. 128, "Earnings per Share," which is effective for financial statements issued for periods ending after December 15, 1997. SFAS 128 supersedes Accounting Principles Board Opinion No. 15 (APB 15) and establishes new standards for the presentation of earnings per share. Under SFAS 128, "Basic Earnings Per Share" excludes dilution and is computed by dividing income available to common stockholders by weighted average shares outstanding. "Diluted Earnings Per Share" reflects the effect of all dilutive outstanding common stock equivalents. The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations, as required by SFAS 128:

For the three months ended

	July 4, 1998	June 28, 1997
Basic EPS		
Net Income(loss)	$ 4,900	$ 6,481
Weighted Average Shares	26,585	26,569
Basic income(loss) per share	$ .184	$ .244
Diluted EPS		
Net Income(loss)	$ 4,900	$ 6,481
Basic Weighted Average shares	26,585	26,569
Effect of Stock options	42	76
Diluted Weighted Average shares	26,627	26,645
Diluted income(loss) per share	$ .184	$ .243

8. DISCONTINUED OPERATIONS

On May 1, 1998, the Board of Directors announced a plan to discontinue the Company's Blood Bank Management Services Business, ("BBMS"). Accordingly, the operating results for BBMS have been segregated from the results for the continuing operations and reported as a separate line on the consolidated statements of operations for all periods presented. For the three months ended July 4, 1998, the operating loss for BBMS of $2,674 was charged to the discontinued operations provision established in the fourth quarter of fiscal year 1998.

The Operating losses for BBMS are detailed as follows:

	July 4, 1998	June 28, 1997
	(in thousands)	
Net Revenues	$ 6,091	$ 2,843
Gross Profit	260	(26)
Operating expenses:		
Research and Development	0	76
Selling, general and administrative	2,934	1,761
Total operating expenses	2,934	1,837
Operating loss	(2,674)	(1,863)
Other expense	(88)	(39)
Taxes	(967)	(666)
Net loss	(1,795)	(1,236)
Charged to Reserve:		
Operating loss (net of taxes)	1,738	--
Reflected on Statement of Operations	$ (57)	$(1,236)

Other income(expense) includes an allocation of corporate interest expense of approximately $88,000 and $39,000 for the three months ended July 4, 1998 and June 28, 1997, respectively. The allocation of corporate interest was calculated based upon the percentage of net assets of BBMS to total domestic assets.

The remaining net assets of BBMS included in the consolidated balance sheet for July 4, 1998 and March 28, 1998 are as follows:

	July 4, 1998	March 28, 1998
	(in thousands)	
Current Assets	$ 5,497	$ 5,167
Net property, plant and equipment	7,559	8,217
Other assets	55	39
Total assets	$13,111	$13,423
Current liabilities and accrued losses	$13,015	$15,760
Other long-term liabilities	1,450	1,450
Total liabilities	$14,465	$17,210

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF CONTINUING OPERATIONS

The table outlines the components of the consolidated statements of income for continuing operations as a percentage of net revenues:

	Percentage of Net Revenues Three Months Ended July 4, 1998	June 28, 1997	Percentage Increase Three Months Ended 1998/97
Net revenues	100.0%	100.0%	(9.4)%
Cost of goods sold	50.0	53.3	(15.0)
Gross Profit	50.0	46.7	(3.0)
Operating Expenses:			
Research and development	5.3	6.2	(22.8)
Selling, general and administrative	34.5	26.1	20.0
Total operating expenses	39.8	32.3	11.8
Operating income	10.1	14.4	(36.2)
Interest expense	(1.4)	(0.7)	75.8
Interest income	1.5	1.2	14.0
Other income	0.3	----	587.5
Income before provision for income taxes	10.6	14.9	(35.8)
Provision for income taxes	3.7	5.2	(35.8)
Earnings from continuing operations	6.9%	9.7%	(35.8)%

Three Months Ended July 4, 1998 Compared to Three Months Ended June 28, 1997

Net revenues in 1998 decreased 9.4% to $72.0 million from $79.5 million in 1997. Without the effects of foreign exchange fluctuations and a non-recurring $7.4 million order in the prior year, net revenues increased 6.0%. Worldwide disposable sales increased approximately .8%. Without the effects of currency, disposable sales increased 7.8%. Sales of disposables products accounted for approximately 95% and 85% of net revenues for 1998 and 1997, respectively. Service revenues generated from equipment repairs performed under preventive maintenance contracts or emergency service billings are included as part of disposables revenues and accounted for approximately .8% and .5% of the Company's net revenues for 1998 and 1997, respectively. Equipment revenues decreased approximately 69.1%. The majority of this decrease was attributable to the $6.0 million in plasma equipment shipped to China during the first quarter of 1997. This revenue was non-recurring in 1998. International sales accounted for approximately 67% of net revenues for both 1998 and 1997.

Gross profit in 1998 decreased $1.1 million from $37.1 million in 1997. As a percentage of net revenues, gross profit percent increased by 3.3% to 50.0% in 1998 from 46.7% in 1997. This increase was the net result of a 6.1 percentage point increase in gross profit percent due to lower product costs in 1998, offset by a 2.8 percentage point decrease in gross profit percent in 1998 due to the unfavorable effects of currency.

The Company expended $3.8 million in 1998 on research and development (5.3% of net revenues) and $4.9 million in 1997 (6.2% of net revenues).

Selling, general and administrative expenses increased to $24.9 million in 1998 from $20.7 million in 1997 and increased as a percentage of net revenues to 34.5% from 26.1%. Approximately $2.6 million of the 1998 expense was related to a provision for certain sales contract receivables from the American Red Cross upon the Company's decision to resolve a dispute with the American Red Cross.

Operating income, as a percentage of net revenues, decreased 4.3 % to 10.1% in 1998 from 14.4% in 1997. The decrease in operating income as a percentage of sales was due to the increase in selling, general and administrative expenses, partially offset by the improvement in gross profit as a percentage of sales.

Interest expense increased in 1998 to $1.0 million from $.6 million in 1997 due to an increase domestically in the average level of borrowings and in interest rates charged as a result of the $40.0 million in fixed rate notes with a coupon rate of 7.05% issued by the Company during the third quarter of last year. Interest income increased only slightly in 1998 to $1.0 million as a result of interest earned on increased domestic cash balances.

Other income increased $.2 million from 1997 to 1998 due to increases in income earned from points on hedging transactions.

The provision for income taxes, as a percentage of pretax income, remained at 35.0% for both 1998 and 1997. The annualized rate for the full

12 months of fiscal 1999 is expected to be approximately 35%.

RESULTS OF DISCONTINUED OPERATIONS

Three Months Ended July 4, 1998 Compared to Three Months Ended June 28, 1997

Net revenues increased 114.3% in 1998 to $6.1 million in 1997. Gross profit in 1998 increased to $.2 million in 1998 from slightly less than zero in 1997 and operating losses increased 43.5% to $(2.7) million in 1998 from $(1.9) million in 1997. The increase in operating losses was the result of operating costs increasing at rates in excess of sales growth.

LIQUIDITY AND CAPITAL RESOURCES

The Company has satisfied its cash requirements principally from internally generated cash flow and borrowings. The Company's need for funds is derived primarily from capital expenditures, acquisitions, new business development and working capital.

During the three months ended July 4, 1998, the Company increased its cash balances by $2.5 million from operating, investing and financing activities which represents an increase of $5.3 million from the $2.8 million utilized by the Company's operating, investing and financing activities during the three months ended June 28, 1997. The increase was largely a result of $33.9 million net cash provided by the Company's operating and investing activities offset by $28.6 million of additional cash utilized by the Company's financing activities.

Operating Activities:

The Company generated $13.2 million in cash from operating activities of continuing operations in 1998 as compared to $5.6 million utilized during 1997. The $18.8 million increase in operating cash flow from continuing operations was a result of $6.6 million in account receivable collections; a $1.1 million decrease in inventory investment and short-term sales-type leases; a $7.7 million decrease in prepaid income taxes as a result of a refund received related to last year's losses; a $3.6 million decrease in other assets; and a $2.6 million swing in accounts payable, accrued expenses and other current liabilities. These increased sources of cash were offset by a decrease in net income adjusted for non-cash items of $2.8 million.

During 1998, the Company's discontinued operations utilized $2.3 million in operating cash flows, an increase of $1.7 million over the $0.6 million of uses in 1997.

Investing Activities

The Company utilized $1.1 million in cash for investing activities from continuing operations in 1998, a decrease of $16.3 million from 1997. During the three months ended July 4, 1998, the Company incurred $3.8 million in capital expenditures net of retirements and disposals. Included in this amount is a $.2 million net increase in long-term demonstration assets. During the three months ended June 28, 1998, the Company utilized $8.4 million for capital expenditures net of retirements and disposals, including $.4 million for net expenditures for long-term demonstration assets. The $4.6 million decrease in expenditures on property, plant and equipment, commercial plasma machines and other revenue generating assets from 1997 to 1998 is due primarily to lower commercial plasma machine placements. Finally, the Company reduced its investment in long-term sales-type leases by $2.8 million in the first quarter of fiscal 1999, compared with an increased investment of $9.0 million in the first quarter of fiscal 1998.

During the three months ended July 4, 1998, the Company invested $0.2 million in discontinued operations related to capital expenditures. This reflects a decrease in capital investing of $0.5 million over the $0.7 million invested during the three months ended June 28, 1997.

Financing Activities:

During the three months ended July 4, 1998, the Company's continuing operations generated cash from operating activities and, as a result paid down a portion of debt.

Net debt decreased $9.6 million to $39.6 million in 1998, including $2.5 million which was utilized by the discontinued operations.

The Company does not expect to repurchase any shares during the current fiscal year. During the quarter ended June 28, 1997, the Company used $5.6 million to repurchase shares of treasury stock.

At July 4, 1998, the Company had working capital of $121.2 million. This reflects an increase of $8.5 million in working capital for the three months ended July 4, 1998. The Company believes its sources of cash are adequate to meet its projected needs.

Year 2000 Compliance

Haemonetics is aware of the potential for industry wide business disruption which could occur due to problems related the "Year 2000 issue." It is the belief of Haemonetics Management that we have a prudent plan in place to address these issues within our company and our supply chain. The components of our plan include: an assessment of internal systems for modification and/or replacement; communication with external vendors to determine their state of readiness to maintain an uninterrupted supply of goods and services to Haemonetics; an evaluation of equipment sold by

Haemonetics to customers as to the ability of the equipment to work properly after the turn of the century; an evaluation of our production equipment as to its ability to function properly after the turn of the century; an evaluation of facility related issues; the retention of technical and advisory expertise to ensure that we are taking prudent action steps; and the development of a contingency plan.

At this time Haemonetics is not aware of any specific internal systems or external vendors issues related to the Year 2000 which would prevent, or seriously impact the Company from continuing operations before, during, or after the turn of the century. Furthermore, we are not aware of any issues related to equipment sold by Haemonetics which would prevent our customers from continuing their operations or which would impact the safety of patients or donors in any way. Haemonetics does not believe that the total cost of Year 2000 compliance for the company will be material to the financial results of the Company.

Although we believe that we are taking prudent action related to the identification and resolution of issues related to the Year 2000 our assessment is still in progress. We may never be able to know with certainty whether certain key vendors are compliant, especially those outside the United States. There are also technical vagaries to logic imbedded within microchips which may prove not feasible or impossible to test.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Not applicable.

Item 2. Changes in Securities

Not applicable.

Item 3. Defaults upon Senior Securities

Not applicable.

Item 4. Submission of Matters to a Vote of Security Holders

Not applicable.

Item 5. Other Information

In accordance with the provisions of Rule 14a-4(c) promulgated under the Securities Exchange Act of 1934, if the Company does not receive notice of a shareholder proposal to be raised at its 1999 Annual Meeting on or before May 8, 1999, then in such event, the management proxies shall be allowed to use their discretionary voting authority when the proposal is raised at the 1999Annual Meeting of Stockholders.

Item 6. Exhibits and Reports on Form 8-K.

(a). Exhibits

The following exhibits will be filed as part of this form 10-Q:

Exhibit 27 Financial Data Schedule

(b). Reports on Form 8-K.

On April 17, 1998, the Company filed a current report on Form 8-K, dated April 16, 1998 to report under Item 5 the declaration of a dividend distribution of Rights in connection with the adoption of a Shareholder Rights Plan.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HAEMONETICS CORPORATION

Date: August 10, 1998

By: /s/ JAMES L. PETERSON

James L. Peterson, President and
Chief Executive Officer

Date: August 10, 1998

By: /s/ RONALD J. RYAN

Ronald J. Ryan, Sr. Vice President of
Finance and Chief Financial Officer,
(Principal Accounting Officer)

3-MOS
APR-03-1999
JUL-04-1998
24,255
0
57,966
840
64,474
188,088
170,180
87,346
331,368
66,830
51,462
0
0
293
198,878
331,368
71,996
71,996
36,026
36,026
3,803
0
979
7,627
2,670
4,957
(57)
0
0
4,900
0.18
0.18

3-MOS
MAR-28-1998
JUN-28-1997
5,622
0
78,589
705
59,012
177,017
200,135
93,387
347,590
69,319
33,603
0
0
293
227,882
347,590
79,485
79,485
42,397
42,397
4,928
0
557
11,873
4,156
7,717
(1,236)
0
0
6,481
0.24
0.24